MRKR

Marker Therapeutics, Inc.

A Houston-based clinical-stage biotech company developing T cell-based immunotherapies for blood cancers and solid tumors. Its signature Multi-Antigen Recognizing (MAR) T cell therapy grows a patient's own tumor-fighting T cells in the lab without genetic modification, unlike engineered CAR-T treatments. The company's roots trace to research at Baylor College of Medicine, and its name comes from the tumor "markers" (antigens) its T cells are trained to spot. The current public company was formed in 2018 when TapImmune Inc. merged with the privately held Marker Therapeutics and took on its name.